Planning to introduce novel tuberculosis vaccines in high burden settings: how could this be done?
- PMID: 36925160
- PMCID: PMC10022833
- DOI: 10.1016/S2214-109X(23)00123-7
Planning to introduce novel tuberculosis vaccines in high burden settings: how could this be done?
Conflict of interest statement
MFC reports payment from Vakzine Project Management and the Serum Institute of India to his institution as an investigator for the VPM1002 infant trials and from Biofabri to his institution as an investigator for the MTBVAC infant trials, in addition to financial support from Biofabri for attending the start up meetings for both trials. HR reports membership on the MTBVAC study team, and membership on Data Safety Monitoring Boards for the EMPIRICAL study and on steering committee for the TB Speed study, and membership of the FAMCRU board (but receiving no payment for any of these roles).
Comment on
-
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.Lancet Glob Health. 2023 Apr;11(4):e546-e555. doi: 10.1016/S2214-109X(23)00045-1. Lancet Glob Health. 2023. PMID: 36925175 Free PMC article.
References
-
- WHO . World Health Organization; Geneva: 2008. Global tuberculosis control: surveillance, planning, financing: WHO report 2008.
-
- WHO. UNAIDS . World Health Organization; Geneva: 2015. Global AIDS response progress reporting.
-
- WHO . World Health Organization; Geneva: 2018. WHO preferred product characteristics for new tuberculosis vaccines.
-
- Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381:2429–2439. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical